Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when
compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ
would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio